[go: up one dir, main page]

HK1252534A1 - 來氟米林的可注射藥物組合物 - Google Patents

來氟米林的可注射藥物組合物

Info

Publication number
HK1252534A1
HK1252534A1 HK18111844.5A HK18111844A HK1252534A1 HK 1252534 A1 HK1252534 A1 HK 1252534A1 HK 18111844 A HK18111844 A HK 18111844A HK 1252534 A1 HK1252534 A1 HK 1252534A1
Authority
HK
Hong Kong
Prior art keywords
lefamulin
pharmaceutical formulations
injectable pharmaceutical
injectable
formulations
Prior art date
Application number
HK18111844.5A
Other languages
English (en)
Inventor
Mathias Ferencic
Werner Heilmayer
Peter Hinsmann
Wolfgang Wicha
Original Assignee
Nabriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH
Publication of HK1252534A1 publication Critical patent/HK1252534A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18111844.5A 2015-06-17 2018-09-14 來氟米林的可注射藥物組合物 HK1252534A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562180871P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
HK1252534A1 true HK1252534A1 (zh) 2019-05-31

Family

ID=56131530

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111844.5A HK1252534A1 (zh) 2015-06-17 2018-09-14 來氟米林的可注射藥物組合物

Country Status (27)

Country Link
US (2) US12121582B2 (zh)
EP (1) EP3310331B1 (zh)
JP (1) JP6818019B2 (zh)
KR (1) KR102656841B1 (zh)
CN (1) CN107810000B (zh)
AU (1) AU2016278774C1 (zh)
BR (1) BR112017026904B1 (zh)
CA (1) CA2989372C (zh)
CY (1) CY1123722T1 (zh)
DK (1) DK3310331T3 (zh)
EA (1) EA033988B1 (zh)
ES (1) ES2843723T3 (zh)
HK (1) HK1252534A1 (zh)
HR (1) HRP20210010T1 (zh)
HU (1) HUE053024T2 (zh)
IL (1) IL256115A (zh)
LT (1) LT3310331T (zh)
MX (1) MX2017015812A (zh)
PH (1) PH12017502319A1 (zh)
PL (1) PL3310331T3 (zh)
PT (1) PT3310331T (zh)
RS (1) RS61327B1 (zh)
SI (1) SI3310331T1 (zh)
TW (1) TWI718158B (zh)
UA (1) UA121240C2 (zh)
WO (1) WO2016202788A1 (zh)
ZA (1) ZA201707998B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4135681A1 (en) 2020-04-17 2023-02-22 Nabriva Therapeutics GMBH Novel therapeutic use of pleuromutilins
CN115413238B (zh) * 2020-04-17 2024-10-25 纳布里瓦治疗有限责任公司 截短侧耳素类化合物的治疗用途
CN115443131A (zh) 2020-04-17 2022-12-06 纳布里瓦治疗有限责任公司 截短侧耳素类化合物的治疗用途
EP4373960A1 (en) * 2021-07-19 2024-05-29 JBS Science Inc. Methods for isolating circulating nucleic acids from urine samples
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
BE1003647A5 (fr) * 1989-02-28 1992-05-12 Syntex Inc Composition pharmaceutique de nicardipine pour administration parenterale.
DE4023848C2 (de) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
US6187746B1 (en) 1997-12-16 2001-02-13 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
BR0109809A (pt) 2000-04-04 2003-01-21 Smithkline Beecham Plc Derivados do carbamato de 2-hidroxi-mutilina para uso antibacteriano
GB0017031D0 (en) 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
RU2416610C2 (ru) * 2004-12-30 2011-04-20 Астекс Терапьютикс Лимитед Фармацевтические соединения
US7790767B2 (en) * 2005-06-27 2010-09-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0515995D0 (en) 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
WO2011002776A1 (en) * 2009-06-29 2011-01-06 Nitric Biotherapeutics, Inc. Pharmaceutical formulations for iontophoretic delivery of an immunomodulator
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
JP6533780B2 (ja) * 2013-05-28 2019-06-19 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 細菌性感染症の治療に用いるためのオキサゾリジノン−キノロン類を含む組み合わせ療法
TWI762573B (zh) * 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化

Also Published As

Publication number Publication date
HRP20210010T1 (hr) 2021-03-05
CA2989372A1 (en) 2016-12-22
TW201716056A (zh) 2017-05-16
CA2989372C (en) 2023-10-03
EA033988B1 (ru) 2019-12-17
EP3310331A1 (en) 2018-04-25
AU2016278774B2 (en) 2021-07-29
PT3310331T (pt) 2021-01-19
MX2017015812A (es) 2018-07-06
CN107810000B (zh) 2021-03-12
TWI718158B (zh) 2021-02-11
BR112017026904B1 (pt) 2023-10-10
JP6818019B2 (ja) 2021-01-20
AU2016278774C1 (en) 2021-11-18
RS61327B1 (sr) 2021-02-26
JP2018517777A (ja) 2018-07-05
SI3310331T1 (sl) 2021-02-26
ES2843723T3 (es) 2021-07-20
CY1123722T1 (el) 2022-05-27
EP3310331B1 (en) 2020-10-14
AU2016278774A1 (en) 2017-12-07
CN107810000A (zh) 2018-03-16
EA201890075A1 (ru) 2018-05-31
PH12017502319A1 (en) 2018-06-25
US12121582B2 (en) 2024-10-22
US20250009885A1 (en) 2025-01-09
LT3310331T (lt) 2021-01-11
BR112017026904A2 (pt) 2018-08-14
US20180360966A1 (en) 2018-12-20
PL3310331T3 (pl) 2021-04-19
IL256115A (en) 2018-02-28
UA121240C2 (uk) 2020-04-27
ZA201707998B (en) 2021-04-28
WO2016202788A1 (en) 2016-12-22
KR102656841B1 (ko) 2024-04-12
DK3310331T3 (da) 2021-01-11
HUE053024T2 (hu) 2021-06-28
KR20180030479A (ko) 2018-03-23

Similar Documents

Publication Publication Date Title
IL287947A (en) Viscosity reduction of pharmaceutical preparations
ES3007987T3 (en) Pharmaceutical formulations
HK1254343A1 (zh) 藥物製劑
HK1252534A1 (zh) 來氟米林的可注射藥物組合物
ZA201707094B (en) Pharmaceutical formulations
IL267279A (en) Pharmaceutical formulations of suvorexant
ZA201705329B (en) Pharmaceutical formulations of racecadotril
IL252729A0 (en) Injectable formulations of acetaminophen
PT3319596T (pt) Composições farmacêuticas
GB201506598D0 (en) Pharmaceutical compositions